|
TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). |
|
|
Honoraria - Celgene; Celgene; Celgene; Celgene |
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Celgene; Celgene; Celgene; Celgene; ERYTECH Pharma (Inst); ERYTECH Pharma (Inst); ERYTECH Pharma (Inst); ERYTECH Pharma (Inst); Halozyme; Halozyme; Halozyme; Halozyme; Shire; Shire; Shire; Shire; VECT-HORUS; VECT-HORUS; VECT-HORUS; VECT-HORUS |
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Shire; Shire; Shire; Shire |
Travel, Accommodations, Expenses - Halozyme; Halozyme; Halozyme; Halozyme; Ipsen; Ipsen; Ipsen; Ipsen; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Shire; Shire; Shire; Shire |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Lilly; Lilly; Lilly; Lilly; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER |
Research Funding - amgen (Inst); amgen (Inst); amgen (Inst); amgen (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst); SERVIER (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; Sandoz; Sandoz; Sandoz; Sandoz; Takeda; Takeda; Takeda; Takeda |
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen; Janssen; Janssen; Janssen; Merck; Merck; Merck; Merck; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche; Takeda; Takeda; Takeda; Takeda |
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sandoz (Inst); Sandoz (Inst); Sandoz (Inst); Sandoz (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; Janssen-Cilag; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche |
|
|
Honoraria - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Celgene; Celgene; Celgene; Celgene; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Servier; Servier; Servier; Servier; Shire; Shire; Shire; Shire; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical |
Consulting or Advisory Role - ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; Incyte; Incyte; Incyte; Incyte; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche Pharma AG; Roche Pharma AG; Roche Pharma AG; Roche Pharma AG; Shire; Shire; Shire; Shire; Sirtex medical; Sirtex medical; Sirtex medical; Sirtex medical |
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Merck KGaA; Merck KGaA; Merck KGaA; Merck KGaA; SERVIER; SERVIER; SERVIER; SERVIER; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical |
Research Funding - Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Sirtex Medical (Inst); Sirtex Medical (Inst); Sirtex Medical (Inst); Sirtex Medical (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; Servier/Shire; Servier/Shire; Servier/Shire; Servier/Shire |
Speakers' Bureau - Prime Oncology; Prime Oncology; Prime Oncology; Prime Oncology |
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Nordic Drugs (Inst); Nordic Drugs (Inst); Nordic Drugs (Inst); Nordic Drugs (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Servier (Inst); Servier (Inst); Servier (Inst); Servier (Inst) |
Travel, Accommodations, Expenses - Abbvie; Abbvie; Abbvie; Abbvie; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre |
|
|
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical |
Speakers' Bureau - Celgene; Celgene; Celgene; Celgene; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical |
|
|
Honoraria - Amgen; Amgen; Amgen; Amgen; Baxalta; Baxalta; Baxalta; Baxalta; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Celgene; Celgene; Celgene; Celgene; Falk Foundation; Falk Foundation; Falk Foundation; Falk Foundation; Halozyme; Halozyme; Halozyme; Halozyme; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER |
Consulting or Advisory Role - Baxalta; Baxalta; Baxalta; Baxalta; Bayer; Bayer; Bayer; Bayer; Celgene; Celgene; Celgene; Celgene; Halozyme; Halozyme; Halozyme; Halozyme; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Shire; Shire; Shire; Shire |
Research Funding - Celgene; Celgene; Celgene; Celgene; Sanofi; Sanofi; Sanofi; Sanofi |
Travel, Accommodations, Expenses - Celgene; Celgene; Celgene; Celgene; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER |
|
|
No Relationships to Disclose |
|
|
Employment - Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma; Synta; Synta; Synta; Synta; Vertex; Vertex; Vertex; Vertex |
|
|
Employment - Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma |
Stock and Other Ownership Interests - Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma |
|
|
Employment - Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma |
Stock and Other Ownership Interests - Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma |
|
|
Employment - Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma |
Stock and Other Ownership Interests - Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma |
Leadership - Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma |
Stock and Other Ownership Interests - Erytech Pharma; Erytech Pharma; Erytech Pharma; Erytech Pharma |
|
|
Stock and Other Ownership Interests - Agenus; Agenus; Agenus; Agenus; BioOncotech; BioOncotech; BioOncotech; BioOncotech; Champions Oncology; Champions Oncology; Champions Oncology; Champions Oncology; Nelum Corp.; Nelum Corp.; Nelum Corp.; Nelum Corp.; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech |
Honoraria - Agenus; Agenus; Agenus; Agenus; InxMed; InxMed; InxMed; InxMed; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Takeda; Takeda; Takeda; Takeda |
Consulting or Advisory Role - Agenus; Agenus; Agenus; Agenus; Bayer; Bayer; Bayer; Bayer; Oncomatrix; Oncomatrix; Oncomatrix; Oncomatrix; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Pharmacyte Biotech; Takeda; Takeda; Takeda; Takeda |
Research Funding - BiolineRx; BiolineRx; BiolineRx; BiolineRx; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma; ERYTECH Pharma |
Patents, Royalties, Other Intellectual Property - Royalties from Myriad for PALB2 patent; Royalties from Myriad for PALB2 patent; Royalties from Myriad for PALB2 patent; Royalties from Myriad for PALB2 patent |
Expert Testimony - Myriad Genetics; Myriad Genetics; Myriad Genetics; Myriad Genetics |
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; BiolineRx; BiolineRx; BiolineRx; BiolineRx; Celgene; Celgene; Celgene; Celgene; Menarini; Menarini; Menarini; Menarini |